Maternal prenatal psychological distress associates with offspring early-life wheezing – FinnBrain Birth Cohort

Emma Puosi1,2,3 | Laura S. Korhonen1,2,3 | Linnea Karlsson1,3,4 | Eeva-Leena Kataja1,3,5 | Heikki Lukkarinen1,2 | Hasse Karlsson1,3,4 | Minna Lukkarinen1,2,3

1Department of Clinical Medicine, FinnBrain Birth Cohort Study, Turku Brain and Mind Center, University of Turku, Turku, Finland
2The Department of Pediatrics and Adolescent Medicine, University of Turku, and Turku University Hospital, Turku, Finland
3Centre for Population Health Research, University of Turku, and Turku University Hospital, Turku, Finland
4The Department of Psychiatry, University of Turku, and Turku University Hospital, Turku, Finland
5The Department of Psychology, University of Turku, Turku, Finland

Abstract

Background: Exposure to prenatal maternal psychological distress may contribute to the development of childhood atopic disorders. Little is known about the importance of distress severity and its duration for the risk. Our aim was to investigate how chronic maternal depressive and anxiety symptoms across gestation influence the risk of wheezing and eczema at child age 24 months.

Methods: The study population was drawn from the FinnBrain Birth Cohort Study, including 1305 mother-infant dyads followed across gestation until the child age of 24 months when the outcomes were mother-reported wheezing ever and doctor-diagnosed eczema. To investigate the risk of wheezing phenotypes, wheezing with and without eczema was separated. Maternal distress was assessed with the Edinburgh Postnatal Depression Scale for depressive and the Symptom Checklist-90 for anxiety symptoms three times during pregnancy, and the chronicity was demonstrated using symptom trajectories composed by latent growth mixture modeling.

Results: Of the children, 219/1305 (17%) had wheezing ever and 285/1276 (22%) had eczema. Risk of wheezing ever was elevated with maternal consistently high depressive symptoms (adjusted odds ratio 2.74; 95% confidence interval 1.37–5.50) or moderate and increasing anxiety symptoms (1.94; 1.06–3.54, respectively). Similarly, wheezing without eczema was associated with consistently high depressive (3.60; 1.63–7.94, respectively) and moderate and increasing anxiety symptoms (2.43; 1.21–4.91, respectively).

Conclusions: Maternal chronic psychological distress across gestation was associated with toddler wheezing and especially wheezing without other atopic features.
1 | INTRODUCTION

Wheezing respiratory illness in early childhood is an expiratory breathing difficulty with multifactorial background, and it may indicate the development of asthma when occurring recurrently.\(^1\) The incidence of childhood asthma has increased during the last decades, and the subsequent socioeconomic burden is considerable.\(^1\) While multiple contributors, for example, hygiene hypothesis have been discovered, much of the increased incidence remains unexplained.\(^2\) Current asthma research in children has mainly focused on postnatal exposures even though factors during gestation such as maternal psychological distress (PD) symptoms during gestation have recently been associated with elevated risk of offspring atopic diseases.\(^2,12\) This association could result from the programming effect of maternal PD predisposing the offspring to aberrant immune responses and altered lung development by interfering with immune functions alongside other integrated systems.\(^13\) Animal studies have shown that chronic prenatal PD exposes the offspring to immune system changes,\(^5\) while only little is known how chronic maternal PD symptoms affect the immune system in human fetuses/infants.\(^14\) Majority of previous prospective birth cohort studies on maternal PD during gestation and later risk of offspring wheezing and asthma included only one timepoint during gestation, and only two investigated stress separately in two trim esters.\(^6-8,10,12,15-19\) It is suggested that exposure to maternal PD during end-gestation, rather than mid-gestation, predisposes older children to atopic diseases, which could be the effect of a sensitive window but also the cumulating effect of chronic PD symptoms.\(^2\) However, our recently published study indicated that chronic PD symptoms across gestation increase the risk for food allergy at the age of 6 months suggesting an early programming effect and altered immune responses\(^14\). Other previous studies have not used standardized analyses on severity and duration of maternal PD symptoms covering the entire gestation.\(^14\) Based on this study, we hypothesized that chronic maternal PD symptoms (depression or anxiety) also influence the offspring risk for later wheezing and eczema.\(^2,6\) We aimed to investigate how chronic PD symptoms associate with (1) wheezing ever or doctor-diagnosed eczema at the age of 24 months and further with (2) with atopic and non-atopic wheezing subtypes, which may serve as indicators for later childhood asthma phenotypes.

Key message

Maternal prenatal chronically elevated psychological distress symptoms were associated with offspring wheezing and eczema at child age 24 months, suggesting altered immunology and increased risk of atopic diseases.

2 | METHODS

2.1 | Study subjects and design

The FinnBrain Birth Cohort Study is population-based, prospective pregnancy cohort investigating the long-term effects of prenatal and early-life exposures on child health outcomes.\(^20\) Originally, the cohort consists of 3808 mothers, 2623 fathers, and 3837 children. The families were recruited by research nurses when attending the free-of-charge ultrasounds at gestational weeks (gwks) 12 in three maternity welfare clinics in the Southwestern Hospital District and Åland Islands in Finland 12/2011–04/2015. To this study, 1368 mother-infant dyads with available primary outcome data at the child age of 24 months were eligible (Figure S1). Of these, the children born preterm (gwks <37) were excluded since the preterm delivery is a risk factor for wheezing (Figure S1).\(^21\) The study conforms to the Declaration of Helsinki, was approved by the Ethics Committee of the Hospital District of Southwest Finland (ETMK:57/180/2011), and commenced only after obtaining written informed consent from the guardians.

2.2 | Exposures

At gwks 14, 24, 34, and at child age 24 months, the maternal PD symptom scores were assessed using the Edinburgh Postnatal Depression Scale (EPDS, range 0–30 points) for the depressive and the Symptom Checklist-90, anxiety scale (SCL-90, range 0–40 points) for the anxiety symptoms.\(^20,22\) Prenatal symptom chronicity and severity assessment was based on the EPDS and SCL-90 scores during entire gestation and modeled as symptom trajectories using latent growth mixture modeling with imputed missing data in Mplus 6.0 (StatModel).\(^23,24\) Five latent curves of

**KEYWORDS**

allergy, anxiety, atopy, child, depression, eczema, prenatal, psychological distress, wheezing

(eczema). This finding supports the theory of intrauterine programming effect by maternal psychological distress on offspring immune system and respiratory morbidity.
depressive symptoms and three of anxiety symptoms were chosen for analyses based on the inspection of Akaike’s information criterion and Bayesian’s information criterion and entropy value (Figures 1 and 2, Table S6). Data for maternal body mass index, smoking, and delivery were derived from the Finnish Medical Birth Register and other data from the parental questionnaires (Table 1). Parental education level was used as the indicator of socioeconomic status. It was divided into three groups (low: ≤12, mid: 12–15, and high: >15 years). Atopic diseases were identified from the question “Have you or at least one of your children had allergies, allergic rhinitis and/or eczema?” (yes/no).

2.3 | Outcomes

The primary outcomes were the maternal report of wheezing ever and doctor-diagnosed eczema at the child age of 24 months according to the standardized questionnaire of The International Study of Asthma and Allergies in Childhood (ISAAC). To demonstrate the susceptibility to diverged immunology after prenatal PD exposure, we categorized the wheezing ever into atopic and non-atopic wheezing subtypes by adding the information of existing doctor-diagnosed eczema. For this purpose, we formed the four-class combination outcome: “wheezing with eczema,” “wheezing without eczema,” “eczema without wheezing,” and “neither wheezing nor eczema.”

2.4 | Statistics

Characteristics and subgroup comparisons were done using the t test, Mann-Whitney U test, or the Pearson chi-square (Tables 1-3). In the primary analyses, the risk for wheezing ever or doctor-diagnosed eczema ever was assessed with the binary logistic regression, first in univariable and then in multivariable analyses. The multivariable analyses were adjusted for known risk factors; for wheezing, prenatal maternal smoking, parental education level, child’s sex, and maternal history of asthma; whereas for eczema, child’s sex, maternal history of atopic diseases, and parental education level. The
TABLE 1  Population characteristics and attrition analysis

| Exposures                                                                 | Cohort N = 3837 | Included N = 1305 | Excluded N = 2532 | p* |
|---------------------------------------------------------------------------|-----------------|-------------------|-------------------|----|
| Maternal characteristics during gestation                                 |                 |                   |                   |    |
| Maternal age at birth, years (SD)                                         | 31 (4.5)        | 31 (4.4)          | 30 (4.8)          | <.001 |
| n = 3684                                                                  | n = 1305        | n = 2532          |                   |    |
| Maternal pre-pregnancy body mass index, kg/m² median (IQR)                 | 24 (22:27)      | 23 (21:27)        | 24 (21:27)        | .16 |
| n = 3684                                                                  | n = 1287        | n = 2297          |                   |    |
| Maternal smoking, nr (%)                                                  |                 |                   |                   |    |
| Quit in early pregnancy                                                   | 274/3748 (7.1)  | 65/1285 (5.1)     | 209/2396 (8.7)    | <.001 |
| Through pregnancy                                                         | 207/3748 (5.4)  | 37/1285 (2.9)     | 170/2396 (7.1)    |    |
| Maternal asthma                                                           | 287/3096 (7.4)  | 108/1249 (8.6)    | 179/1847 (9.7)    | .33 |
| Maternal atopic diseases                                                  | 1299/3096 (34)  | 537/1249 (43)     | 762/1847 (41)     | .34 |
| Maternal asthma and/or atopic diseases                                    | 1354/3096 (44)  | 558/1249 (45)     | 796/1847 (43)     | .39 |
| Maternal use of inhaled or oral corticosteroids, nr (%)                   | 134/3690 (3.5)  | 20/1287 (1.6)     | 114/2403 (4.7)    | <.001 |
| Parental education level                                                  |                 |                   |                   |    |
| Up to 12 years                                                            | 1070/3163 (34)  | 303/1259 (24)     | 767/1904 (40)     | <.001 |
| Between 13 and 15 years                                                   | 1077/3163 (43)  | 446/1259 (35)     | 631/1904 (33)     |    |
| Over 15 years                                                             | 1016/3163 (32)  | 510/1259 (41)     | 506/1904 (27)     |    |
| EPDS trajectories                                                          |                 |                   |                   |    |
| *Moderate and Stable*                                                     | N/A             | 292/1293 (23)     | N/A               |    |
| *Low and Increasing*                                                      | 274/3096 (9.1)  | 65/1285 (5.1)     | 209/2396 (8.7)    | <.001 |
| *Consistently High*                                                       | 207/3748 (5.4)  | 37/1285 (2.9)     | 170/2396 (7.1)    |    |
| *High and Decreasing*                                                     | 287/3096 (7.4)  | 108/1249 (8.6)    | 179/1847 (9.7)    | .33 |
| *Consistently Low*                                                        | 1299/3096 (34)  | 537/1249 (43)     | 762/1847 (41)     | .34 |
| SCL-90 trajectories                                                        |                 |                   |                   |    |
| *High and Decreasing*                                                     | N/A             | 53/1292 (4.1)     | N/A               |    |
| *Moderate and Increasing*                                                 | 274/3096 (9.1)  | 65/1285 (5.1)     | 209/2396 (8.7)    | <.001 |
| *Consistently Low*                                                        | 207/3748 (5.4)  | 37/1285 (2.9)     | 170/2396 (7.1)    |    |
| Infant characteristics at birth                                           |                 |                   |                   |    |
| Gestational age, weeks median (IQR)                                       | 40 (39:41) n = 3762 | 40 (39:41) n = 1305 | 40 (39:41) n = 2353 | <.001 |
| Birthweight, g (SD)/length, cm (SD)                                       | 3500 (540)/51 (2.4) | 3600 (480)/51 (2.0) | 3500 (590)/50 (2.7) | <.001/ <.001 |
| Male sex, nr (%)                                                          | 1961/3748 (51)  | 698/1305 (54)     | 1263/2443 (52)    | .30 |
| One or more older siblings (%)                                            | 975/2254 (43)   | 606/1305 (46)     | 1952/2532 (77)    | <.001 |
| Older siblings with mother-reported atopic diseases                        | 444/3096 (12)   | 180/1249 (14)     | 264/1847 (14)     | .93 |
| Older siblings with mother-reported asthma                                 | 97/3096 (2.5)   | 36/1249 (2.9)     | 61/1847 (3.3)     | .51 |
| Delivery with cesarean section                                            | 298/3690 (3.5)  | 98/1287 (7.6)     | 200/2403 (8.3)    | .45 |
| Doctor visit at age 12 months                                              | 302/3837 (7.9)  | 193/1113 (15)     | 109/525 (21)      | .056 |
| Maternal characteristics at child age 24 months                           |                 |                   |                   |    |
| EPDS point medians (range 0–30) (IQR)                                     | 4.0 (1.0–7.0)   | 4.0 (1.0–7.0)     | 4.0 (2.0–8.0)     | .31 |
| n = 1366                                                                  | n = 1291        | n = 78            |                   |    |
| SCL point medians (range 0–40) (IQR)                                      | 1.1 (0.0–4.0)   | 1.1 (0.0–4.0)     | 2.0 (0.0–5.0)     | .67 |
| n = 1366                                                                  | n = 1292        | n = 77            |                   |    |

Abbreviations: BMI, body mass index; CI, confidence interval; EPDS, The Edinburgh Postnatal Depression Scale; gwks, gestational weeks; IQR, interquartile range; N/A, not applicable; OR, odds ratio; SCL-90, The Symptom Checklist-90, anxiety scale; SD, standard deviation.

*Indicates the comparisons with “excluded” as a reference group.
| Exposures                                                                 | No wheezing $(n = 1086)$ | Wheezing ever $(n = 219)$ | $p^a$ | No eczema $(n = 991)$ | Doctor-diagnosed eczema $(n = 285)$ | $p^a$ |
|---------------------------------------------------------------------------|--------------------------|--------------------------|-------|----------------------|------------------------------------|-------|
| **Population characteristics of the included at 24 months**               |                          |                          |       |                      |                                    |       |
| **Maternal characteristics during gestation**                            |                          |                          |       |                      |                                    |       |
| Maternal age at birth, years (SD)                                        | 31 (4.4)                 | 31 (4.2)                 | .42   | 31 (4.3)             | 31 (4.4)                           | .10   |
| $n = 912$                                                                 | $n = 183$                |                          |       |                      |                                    |       |
| Maternal pre-pregnancy body mass index, kg/m² median (IQR)                | 23 (21:26)               | 24 (21:28)               | .21   | 23 (21:26)           | 24 (21:27)                         | .86   |
| $n = 1070$                                                                | $n = 217$                |                          |       |                      |                                    |       |
| **Maternal smoking, nr (%)**                                             |                          |                          |       |                      |                                    |       |
| Quit in early pregnancy                                                  | 52/1068 (4.9)            | 13/217 (6.0)             | .79   | 50/975 (5.1)         | 15/283 (5.3)                       | .93   |
| Through pregnancy                                                        | 31/1066 (2.9)            | 6/217 (2.8)              |       | 27/975 (2.8)         | 9/283 (3.2)                        |       |
| Maternal asthma b                                                        | 78/1042 (7.5)            | 30/207 (15)              | .001  | 76/950 (8.0)         | 10/272 (9.2)                       | .53   |
| Maternal atopic diseases c                                               | 435/1042 (42)            | 102/207 (49)             | .046  | 379/950 (40)         | 148/272 (54)                       | <.001 |
| Maternal asthma and/or atopic diseases                                   | 471/1082 (44)            | 115/223 (52)             | .032  | 414/990 (42)         | 1.6/286 (5.6)                      | <.001 |
| Maternal use of inhaled or oral corticosteroids, nr (%)                  | 17/1070 (1.6)            | 3/217 (1.4)              | .82   | 13/977 (1.3)         | 6/283 (2.1)                        | .34   |
| **Parental education level**                                             |                          |                          |       |                      |                                    |       |
| Up to 12 years                                                           | 249/1050 (24)            | 54/209 (26)              | .014  | 221/952 (23)         | 72/271 (27)                        | .053  |
| Between 13 and 15 years                                                  | 373/1050 (36)            | 73/209 (35)              |       | 331/952 (35)         | 104/271 (38)                       |       |
| Over 15 years                                                            | 428/1050 (41)            | 82/209 (39)              |       | 400/952 (42)         | 95/271 (35)                        |       |
| **EPDS trajectories nr (%)**                                             |                          |                          |       |                      |                                    |       |
| "Moderate and Stable"                                                    | 246/1077 (23)            | 52/215 (24)              | .02   | 218/973 (22)         | 73/282 (26)                        | .64   |
| "Low and Increasing"                                                     | 24/1077 (2.2)            | 5/215 (2.3)              |       | 22/973 (2.3)         | 7/282 (2.5)                        |       |
| "Consistently High"                                                      | 28/1077 (2.6)            | 15/215 (7.0)             |       | 32/973 (3.3)         | 8/282 (2.8)                        |       |
| "High and Decreasing"                                                    | 42/1077 (3.9)            | 8/215 (3.7)              |       | 35/973 (3.6)         | 13/282 (4.6)                       |       |
| "Consistently Low"                                                       | 737/1077 (68)            | 135/215 (64)             |       | 666/973 (68)         | 181/282 (64)                       |       |
| **SCL-90 trajectories, nr (%)**                                          |                          |                          |       |                      |                                    |       |
| "High and Decreasing"                                                    | 43/1077 (4.0)            | 10/215 (4.7)             | .12   | 33/973 (3.4)         | 16/282 (5.7)                       | .049  |
| "Moderate and Increasing"                                                | 50/1077 (4.6)            | 17/215 (79)              |       | 45/973 (4.6)         | 20/282 (7.1)                       |       |
| "Consistently Low"                                                       | 984/1077 (91)            | 188/215 (87)             |       | 895/973 (92)         | 246 (87)                           |       |
| **Infant characteristics at birth**                                       |                          |                          |       |                      |                                    |       |
| Gestational age, weeks (SD)                                              | 40 (1.2)                 | 40 (1.3)                 | .04   | 40.0 (1.2)           | 39.9 (1.2)                         | .56   |
| $n = 1086$                                                                | $n = 219$                |                          |       |                      |                                    |       |
| Birthweight, g (SD)/length, cm (SD)                                      | 3600 (470)/51 (2.0)      | 3600 (490)/51 (2.0)      | .72/.67| 3600 (470)/51 (2.1)  | 3600 (470)/51 (1.9)                | .58/.97|
| $n = 1070$/$n = 1062$                                                   | $n = 218/n = 218$        |                          |       |                      |                                    |       |
| Male sex, nr (%)                                                         | 553/1086 (51)            | 145/219 (66)             | <.001 | 521/991 (53)         | 159/285 (56)                       | .34   |
| One or more older siblings (%)                                           | 496/1086 (46)            | 110/219 (50)             | .12   | 463/983 (47)         | 126/284 (44)                       | .42   |

(Continues)
TABLE 2  (Continued)

| Exposures | No wheezing (n = 1086) | Wheezing ever (n = 219) | p* | No eczema (n = 991) | Doctor-diagnosed eczema (n = 285) | p*
|-----------|------------------------|------------------------|----|--------------------|----------------------------------|----
| Older siblings with mother-reported asthma | 24/1042 (2.3) | 12/207 (5.8) | .006 | 28/950 (2.9) | 7/272 (2.6) | .74
| Older siblings with mother-reported atopic diseases | 145/1042 (14) | 35/207 (17) | .26 | 118/950 (12) | 59/272 (22) | <.001
| Delivery with cesarean section, nr (%) | 83/1070 (7.8) | 15/217 (6.9) | .67 | 71/977 (7.3) | 23/283 (8.1) | .63
| Doctor visit at age 12 months | 140/930 (15) | 35/183 (24) | .26 | 71/977 (7.3) | 23/283 (8.1) | .63

Maternal characteristics at child age 24 months

- EPDS point medians (range 0–30) (IQR) 3.0 (1.0–7.0) n = 1074
- SCL point medians (range 0–40) (IQR) 1.0 (0.0–4.0) n = 1075

Abbreviations: BMI, body mass index; CI, confidence interval; EPDS, The Edinburgh Postnatal Depression Scale; gwks, gestational weeks; IQR, interquartile range; N/A, not applicable; OR, odds ratio; SCL-90, The Symptom Checklist-90, anxiety scale; SD, standard deviation. Bold values indicate significance of P < .05.

*Indicates the group comparisons.

bThe correlation between maternal and sibling asthma in the cohort, p = .003

cThe correlation between maternal and sibling atopic diseases in the cohort, p < .001.

3.1 Study population and characteristics

At the child age of 24 months, maternal questionnaires including data for wheezing were available from 1368/3837 (36%) and for eczema from 1335/3837 (35%) of the cohort children (Figure S1). Children whose mothers did not return the 24-month questionnaire were excluded (Table 2, Figure S1). From these 1305 children, the number of children with available outcome data for wheezing was 53 (4%), wheezing without eczema 141 (12%), and wheezing with eczema 285 (22%). (Table 2, and Figure S1). Based on the four-class combination outcome, the number of children with wheezing was 53 (4%), wheezing without eczema 141 (12%), and eczema 37 (3%) (Table 3).

3.2 RESULTS

Impact of chronic depressive and anxiety symptoms on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzed using symmetric trajectories on the outcomes was analyzes were adjusted for parental education level, children sex, maternal prenatal smoking, and history of asthma and/or atopic diseases as a combined variable. In the supplementary analyses, diseases was the reference group (Table S4, Figures 1 and 2). The non-wheezing nor eczema was the reference group (Table S4). For the four-class combination outcome, the number of children with wheezing was 53 (4%), wheezing without eczema 141 (12%), and eczema 37 (3%) (Table S5). The p-value < .05 was regarded as significant, and 95% confidence interval (CI) was used. Analyses were performed using the IBM SPSS 27.0 software (SPSS Inc.).
TABLE 3  Population characteristics of the included at 24 months

| Exposures                                      | Wheezing with eczema (n = 53) | Wheezing without eczema (n = 154) | Eczema without wheezing (n = 231) | Neither wheezing nor eczema (n = 829) | p*  |
|------------------------------------------------|-------------------------------|-----------------------------------|-----------------------------------|--------------------------------------|-----|
| Maternal characteristics during gestation      |                               |                                   |                                   |                                      |     |
| Maternal age at birth, years (SD)              | 31 (3.4)                      | 32 (4.4)                          | 32 (4.4)                          | 32 (4.4)                             | .27 |
| Maternal smoking, nr (%)                       |                               |                                   |                                   |                                      |     |
| Quit in early pregnancy                        | 4/53 (7.5)                    | 8/152 (5.3)                       | 11/229 (4.8)                      | 41/815 (5.0)                        | .71 |
| Through pregnancy                              | 3/53 (5.7)                    | 2/152 (1.3)                       | 6/229 (2.6)                       | 25/815 (3.1)                        |     |
| Maternal asthma b                              | 7/48 (15)                     | 18/147 (12)                       | 18/223 (8.1)                      | 58/795 (7.3)                        | .09 |
| Maternal atopic diseases c                     |                               |                                   |                                   |                                      |     |
| Maternal asthma and/or atopic diseases         | 29/52 (56)                    | 76/158 (48)                       | 130/233 (55.8)                    | 334/824 (41)                        |     |
| Maternal use of inhaled or oral corticosteroids, nr (%) |                               |                                   |                                   |                                      |     |
| Parental education level                       |                               |                                   |                                   |                                      |     |
| Up to 12 years                                 | 14/48 (29)                    | 35/149 (24)                       | 58/223 (26)                       | 186/803 (23)                        | .039|
| Between 13 and 15 years                        | 17/48 (35)                    | 52/149 (35)                       | 87/223 (39)                       | 279/803 (35)                        |     |
| Over 15 years                                  | 17/48 (35)                    | 62/149 (42)                       | 78/223 (35)                       | 338/803 (42)                        |     |
| EPDS trajectories nr (%)                       |                               |                                   |                                   |                                      |     |
| "Moderate and Stable"                          | 13/51 (26)                    | 37/152 (24)                       | 60/231 (26)                       | 181/821 (22)                        | .10 |
| "Low and Increasing"                           | 2/51 (3.9)                    | 3/152 (2.0)                       | 5/231 (2.2)                       | 19/821 (2.3)                        |     |
| "Consistently High"                            | 1/51 (2.0)                    | 12/152 (7.9)                      | 7/231 (3.0)                       | 20/821 (2.4)                        |     |
| "High and Decreasing"                          | 1/51 (2.0)                    | 7/152 (4.6)                       | 12/231 (5.2)                      | 28/821 (3.4)                        |     |
| "Consistently Low"                             | 34/51 (67)                    | 93/152 (61)                       | 147/231 (64)                      | 573/821 (70)                        |     |
| SCL-90 trajectories, nr (%)                    |                               |                                   |                                   |                                      |     |
| "High and Decreasing"                          | 1/51 (2.0)                    | 7/152 (4.6)                       | 15/231 (6.5)                      | 26/821 (3.2)                        | .03 |
| "Moderate and Increasing"                      | 5/51 (9.8)                    | 12/152 (7.9)                      | 15/231 (6.5)                      | 33/821 (3.2)                        |     |
| "Consistently Low"                             | 45/51 (89)                    | 133/152 (88)                      | 201/231 (87)                      | 762/821 (93)                        |     |
| Infant characteristics at birth                |                               |                                   |                                   |                                      |     |
| Gestational age, weeks (SD)                    | 39.6 (1.3)                    | 39.9 (1.3)                        | 40.0 (1.2)                        | 40.0 (1.2)                          | .10 |
| Birthweight, g (SD)/length, cm (SD)            | 3600 (500)/51 (2.0)           | 3600 (490)/51 (2.0)               | 3600 (460)/51 (1.9)               | 3600 (470)/51 (2.1)                 | .92 |
| Male sex, nr (%)                               | 42/52 (79)                    | 95/154 (61)                       | 116/231 (50)                      | 423/821 (51)                        | <.001|
| One or more older siblings (%)                 | 27/52 (51)                    | 79/154 (51)                       | 99/231 (43)                       | 384/829 (46)                        | .38 |
| Older siblings with mother-reported asthma b   | 2/48 (4.2)                    | 9/147 (6.1)                       | 5/233 (2.2)                       | 19/795 (2.4)                        | .08 |
| Older siblings with mother-reported atopic diseases c | 10/48 (21)                   | 24/147 (16)                       | 49/223 (22)                       | 94/795 (12)                         | .001|
| Delivery with cesarean section, nr (%)         | 3/53 (5.7)                    | 11/152 (7.2)                      | 20/229 (8.7)                      | 60/817 (7.3)                        | .85 |
| Doctor visit at age 12 months                  | 15/40 (38)                    | 34/133 (26)                       | 37/187 (20)                       | 98/721 (14)                         | <.001|
| Maternal characteristics at child age 24 months|                               |                                   |                                   |                                      |     |
| EPDS point medians (range 0–30) (IQR)          | 5.0 (2.0–8.8)                 | 4.0 (2.0–7.0)                     | 4.0 (1.0–8.0)                     | 3.0 (1.0–7.0)                       | .009|
| SCL point medians (range 0–40) (IQR)           | 2.5 (1.0–7.0)                 | 2.0 (0.0–5.0)                     | 2.0 (0.0–5.0)                     | 1.0 (0.0–4.0)                       | .01 |

Abbreviations: BMI, body mass index; CI, confidence interval; EPDS, The Edinburgh Postnatal Depression Scale; gwks, gestational weeks; IQR, interquartile range; N/A, not applicable; OR, odds ratio; SCL-90, The Symptom Checklist-90, anxiety scale; SD, standard deviation. Bold values indicate significance of P < .05.

*Indicates the comparisons with "Neither wheezing nor eczema" as the reference group.

The correlation between maternal and sibling asthma in the cohort, p = .003

The correlation between maternal and sibling atopic diseases in the cohort, p < .001
Table 4: Risk of wheezing or doctor-diagnosed atopic eczema at 24 months

| Maternal reported exposures during gestation | Wheezing ever OR (95% CI) | p<sup>a</sup> | Doctor-diagnosed eczema OR (95% CI) | p<sup>a</sup> |
|---------------------------------------------|---------------------------|-------------|------------------------------------|-------------|
| Unadjusted analyses                          |                           |             |                                    |             |
| Maternal atopic diseases                     | 1.4 (1.0–1.8)             | .046        | 1.8 (1.4–2.4)                      | <.001       |
| Maternal asthma                              | 2.1 (1.3–3.3)             | .001        | 1.2 (0.73–1.9)                     | .53         |
| Maternal smoking during pregnancy            |                           |             |                                    |             |
| Quit in early pregnancy<sup>a</sup>          | 1.2 (0.67–2.3)            | .50         | 1.0 (0.57–1.9)                     | .90         |
| Through pregnancy<sup>a</sup>                | 0.96 (0.40–2.3)           | .93         | 1.2 (0.54–2.49)                    | .71         |
| Older children with mother-reported atopic diseases | 1.3 (0.84–1.9) | .26 | 2.0 (1.4–2.8) | <.001 |
| Older children with mother-reported asthma    | 2.6 (1.3–5.3)             | .008        | 0.87 (0.38–2.0)                    | .75         |
| Male sex vs. female sex                      | 1.9 (1.4–2.6)             | <.001       | 1.1 (0.87–1.5)                     | .34         |
| Parental education level                     |                           |             |                                    |             |
| Up to 12 years<sup>a</sup>                  | 2.6 (1.4–4.7)             | .002        | 1.4 (0.95–1.9)                     | .090        |
| Between 13 and 15 years<sup>a</sup>         | 1.8 (1.1–3.0)             | .032        | 1.3 (0.95–1.8)                     | .11         |
| Over 15 years<sup>a</sup>                   | 1.0                       |             | 1.0                                 |             |
| EPDS trajectories with "Consistently Low" as reference | | | | |
| "Moderate and Stable"                        | 1.15 (0.81–1.64)          | .42         | 1.23 (0.90–1.68)                   | .19         |
| "Low and Increasing"                         | 1.14 (0.43–3.03)          | .80         | 1.17 (0.49–2.78)                   | .72         |
| "Consistently High"                          | 2.93 (1.52–5.62)          | .001        | 0.92 (0.42–2.03)                   | .84         |
| "High and Decreasing"                        | 1.04 (0.48–2.26)          | .92         | 1.37 (0.71–2.64)                   | .35         |
| SCL-90 trajectories with "Consistently Low" as reference | | | | |
| "High and Decreasing"                        | 1.22 (0.60–2.47)          | .59         | 1.76 (0.96–3.26)                   | .070        |
| "Moderate and Increasing"                    | 1.78 (1.00–3.15)          | .048        | 1.62 (0.94–2.79)                   | .084        |
| Adjusted analyses                            |                           |             |                                    |             |
| EPDS trajectories with "Consistently Low" as the reference | | | | |
| "Moderate and Stable"                        | 1.07 (0.74–1.55)          | .74         | 1.25 (0.91–1.73)                   | .17         |
| "Low and Increasing"                         | 1.64 (0.60–4.51)          | .34         | 1.15 (0.45–3.00)                   | .77         |
| "Consistently High"                          | 2.74 (1.37–5.50)          | .005        | 0.93 (0.41–2.09)                   | .86         |
| "High and Decreasing"                        | 0.99 (0.45–2.20)          | .98         | 1.52 (0.78–3.00)                   | .22         |
| Maternal atopic diseases                     | N/A                       |             | 1.8 (1.4–2.4)                      | <.001       |
| Maternal asthma                              | 2.2 (1.4–3.5)             | <.001       | N/A                                 |             |
| Maternal asthma and/or atopic diseases       | N/A                       |             |                                    |             |
| Male sex vs. female sex                      | 1.8 (1.3–2.5)             | <.001       | 1.1 (0.84–1.5)                     | .48         |
| Maternal smoking during pregnancy            | 1.0 (0.42–2.2)            | .95         |                                    |             |
| Parental education level                     |                           |             |                                    |             |
| Up to 12 years<sup>a</sup>                  | 1.1 (0.71–1.6)            | .78         | 1.3 (0.92–1.9)                     | .13         |
| Between 13 and 15 years<sup>a</sup>         | 1.1 (0.74–1.5)            | .77         | 1.4 (1.0–1.9)                      | .037        |
| Over 15 years<sup>a</sup>                   | 1.0                       |             | 1.0                                 |             |
| SCL-90 trajectories with "Consistently Low" as the reference | | | | |
| "High and Decreasing"                        | 1.27 (0.61–2.6)           | .52         | 1.89 (1.00–3.55)                   | .049        |
| "Moderate and Increasing"                    | 1.94 (1.1–3.5)            | .032        | 1.48 (0.83–2.63)                   | .18         |
| "Maternal atopic diseases"                   | N/A                       |             | 1.8 (1.37–2.38)                    | <.001       |
| Maternal asthma                              | 2.2 (1.4–3.5)             | <.001       | N/A                                 |             |
3.2 | The primary analysis

3.2.1 | Risk of wheezing at age 24 months

In the unadjusted analyses, wheezing ever associated with maternal asthma and atopic diseases, gestational weeks at delivery, male sex, mother-reported asthma in older siblings, and parental education level (Tables 2 and 3). In the EPDS trajectory model, the risk was elevated with the “Consistently High” trajectory (odds ratio [OR] 2.74; 95% CI 1.37–5.50; p = .004) (Table 3, Figures 1 and 2). Likewise, SCL-90 trajectory of “Moderate and Increasing” symptoms was associated with increased risk of wheezing (Table 4, Figures 1 and 2). In the adjusted analyses, the results remained unchanged for both depressive and anxiety symptom trajectories (Table 4).

3.2.2 | Risk of eczema at 24 months

In the unadjusted analysis, doctor-diagnosed eczema at 24 months associated with atopic diseases of mothers and older siblings (Table 3). Prenatal maternal depressive or anxiety symptom trajectories did not associate with doctor-diagnosed eczema (Table 3, Figures 1 and 2). After adjustments, the “High and Decreasing” SCL trajectory was associated with increased risk for eczema (OR 1.89; 95% CI 1.00–3.55; p = .049) (Table 4).

3.3 | The secondary analysis

3.3.1 | Risk in four-class combination outcome

In the unadjusted analysis, the risk for wheezing without eczema was elevated with the EPDS trajectory of “Consistently High” (OR 3.40; 95% CI 1.75–7.81; p = .001) and SCL-90 trajectory of “Moderate and Increasing” (2.08; 1.05–4.14; p = .036, respectively). The risk for eczema without wheezing was elevated with the SCL-90 trajectory of “High and Decreasing” (2.19; 1.14–4.21; p = .019) (Table S3). Adjustments did not change the results (Table S3). In all trajectory analyses, the “neither wheezing nor eczema” was the reference group.

3.4 | The supplementary analyses

The PD symptom scores were studied as continuous variables at each timepoint to illustrate the role of distress exposure separately in each trimester. The risk of wheezing ever was increased in the first and last trimesters when using the continuous EPDS scores and in the second and last trimesters when using the continuous SCL-90 scores (Table S2).

The chronic nature of maternal PD symptoms is illustrated with correlation analysis between PD symptoms during gestation and at 24 months (Table S4). The associations between EPDS trajectories during gestation and wheezing remained unchanged after adjusting for maternal PD symptoms at the child age of 24 months, but not between SCL-90 trajectories (Table S5). However, the associations remained unchanged when the risk of wheezing and eczema was examined in the four-class combination outcome of “Wheezing without eczema” and “Eczema without wheezing” (Table S5).

4 | DISCUSSION

In keeping with earlier studies, we demonstrate that maternal PD during gestation associates with atopic disorders in offspring. Furthermore, we found that mother-experienced PD symptoms that are chronically elevated across gestation, assessed in three timepoints, associated with offspring wheezing and eczema at the age of 24 months. This is the first study on early childhood asthma which observed maternal PD across gestation and
applied latent growth curve modeling in composing the trajectories for chronicity/severity of the PD symptoms.\textsuperscript{14} Our finding is in line with our previous study where maternal chronic PD associated with offspring food allergy at the infant age of 6 months.\textsuperscript{14} Our study also sheds new light into the effects of chronic maternal PD resulting in varied risk for different wheezing subtypes.\textsuperscript{2}

The novelty of our study was the creation of PD symptom trajectories enabling the investigation of symptom severity and chronicity on the outcomes. In previous studies on prenatal PD and atopic diseases, the questionnaires and distress types and timing have been heterogenous.\textsuperscript{2} The studies to date have used different validated questionnaires of depressive and anxiety symptoms\textsuperscript{3,7,9} but also self-reported negative life events or other stressful situations.\textsuperscript{8,12,18,19} The timing of these exposures during gestation has varied between studies,\textsuperscript{2} but also inside studies, a single time point at any time during gestation,\textsuperscript{8} at one trimester,\textsuperscript{7,10-12,18,19} at two trimesters (2nd and 3rd),\textsuperscript{4} or before and after gwks 18.\textsuperscript{3} Derived from previous studies the third trimester may be the most vulnerable time regarding PD exposure.\textsuperscript{7} However, our study shows that chronic depressive and anxiety symptoms may be risk factor for wheezing and eczema and this finding is endorsed by the aligned results of PD symptoms per the time point assessment. We adjusted analyses for maternal atopic diseases or asthma since the correlation between mother/sibling atopic diseases and asthma was significant. Male sex associated with wheezing, as expected.\textsuperscript{21}

Possible reporting bias because of maternal distress symptoms was acknowledged, and therefore, we also adjusted for the PD symptoms at 24 months.\textsuperscript{27} Also, we acknowledge that the attrition could affect the generalizability of the results particularly in the population with accumulated risk factors as maternal PD and lower socioeconomic status were related to attrition. The potential bias resulting from these characteristics in the attrition may dilute the observed associations as the subjects with higher PD symptoms were underrepresented.

To provide new insights into underlying aberrant immune system of different early childhood wheezing subtypes, a four-class combination outcome was applied. For this, we combined wheezing ever and doctor-diagnosed eczema to model the simplified outcomes of “wheezing with eczema,” “wheezing without eczema,” “eczema without wheezing,” and “neither wheezing nor eczema.” They were intended to anticipate the atopic/non-atopic wheezing subtypes, and further, the early phenotypes of atopic/non-atopic asthma. Noteworthy is that exposure to prenatal chronic PD was associated with wheezing without eczema, but not with wheezing with eczema or eczema without wheezing, suggesting that prenatal chronic PD predisposes the offspring toward non-atopic wheezing subtype. However, we acknowledge the statistical power issue caused by relatively small cell sizes, and therefore, conclusions should be made with caution. We hope that these preliminary findings inspire future research as they support the previous studies showing that the susceptibility to diverged immune responses leading to school-age atopic or non-atopic asthma can be seen during the first year of life implying that asthma programming occurs prenatally because of genetic predisposition and environmental exposures.\textsuperscript{2,5,28,29} In addition, previously has been shown that school-age atopic and non-atopic asthma have different early-life risk factors; that is, atopic asthma has concomitant sensitization and/or eczema in infancy whereas maternal smoking during gestation has associated with non-atopic asthma.\textsuperscript{28,29} In current study, maternal prenatal smoking did not associate with wheezing ever or wheezing without eczema, and importantly, maternal depressive and anxiety symptoms did not associate with smoking either. This underlines the notion that prenatal PD may be an independent risk factor for offspring non-atopic wheezing subtype. Prenatal exposures may partly explain the non-genetic variability seen in childhood asthma phenotypes interfering with the immune system and inducing the shift toward Th2-dominant predisposition. The allergen-specific immunoglobulin E was not tested here since sensitization to aeroallergens develops later in general population and its value indicating asthma risk in early life is decreased.\textsuperscript{30} Possible simultaneously mediating mechanisms might include the elevated levels of maternal glucocorticoids and/or cytokines resulting in placental dysregulation, impaired fetal maturation of HPA axis, and altered glucocorticoid levels.\textsuperscript{2,5}

The strengths include the large and non-selected sample of 1305 mother-infant dyads from prospective, population-based pregnancy cohort without major exclusion criteria. It can be perceived as an unselected sample of the general population and therefore represents the maternal and paternal prenatal period of depressive and anxiety symptoms adequately. In general population, the prevalence of wheezing ever before the child age of three years is approximately 20% and for childhood eczema approximately 20%.\textsuperscript{26,31} In current study, the prevalence of wheezing ever and eczema was within expected. The outcomes were based on the structured and widely used ISAAC questionnaire which makes comparison between studies feasible.\textsuperscript{25} In earlier studies on prenatal PD exposure, the outcomes have varied greatly including mother-reported wheezing,\textsuperscript{10} mother-reported doctor-diagnosed wheeze and asthma,\textsuperscript{3,7} mother-reported doctor-diagnosed eczema,\textsuperscript{8,9,11} only mother-reported,\textsuperscript{4,12} and ISAAC-based eczema,\textsuperscript{11} ranging between 1 and 14 years.\textsuperscript{2} The use of mother-reported questionnaires poses a possible reporting bias, also in our study. The review of medical charts would have provided more accurate outcomes, but as our study population originates from large birth cohort with multiple simultaneous multi-disciplined sub-studies, the number of questions were restricted. We would have benefitted from the wheezing severity or number of wheezing episodes, but it was unachievable to examine children during every wheezing episode.

In conclusion, mother-experienced chronic PD symptoms during gestation were associated with elevated risk of offspring wheezing and non-atopic type of wheezing during the first two years of life. The findings highlight the influence of prenatal PD exposure on immune system and support the theory of intrauterine programming effect of maternal PD leading to atopic diseases and respiratory morbidity.\textsuperscript{2}
REFERENCES

1. Beasley R, Semprini A, Mitchell EA. Risk factors for asthma: is prevention possible? Lancet. 2015;386:1075-1085. doi:10.1016/S0140-6736(15)00156-7
2. Flanigan C, Sheikh A, DunnGalvin A, Brew BK, Almqvist C, Nwaru BI. Prenatal maternal psychosocial stress and offspring’s asthma and allergic disease: a systematic review and meta-analysis. Clin Exp Allergy. 2018;48(4):403-414. 10.1111/cea.13091
3. Cookson H, Granell R, Joinson C, Ben-Shlomo Y, Henderson AJ. Mothers’ anxiety during pregnancy is associated with asthma in their children. J Allergy Clin Immunol. 2009;123(4):847-853.e11. doi:10.1016/j.jaci.2009.01.042. http://www.ncbi.nlm.nih.gov/pubmed/19348924
4. Hartwig IRV, Sly PD, Schmidt LA, et al. Prenatal adverse life events increase the risk for atopic diseases in children, which is enhanced in the absence of a maternal atopic predisposition. J Allergy Clin Immunol. 2014;134:160-169. doi:10.1016/j.jaci.2014.01.033
5. Veru F, Laplante DP, Luahesi G, King S. Prenatal maternal stress exposure and immune function in the offspring. Stress. 2014;17(2):133-148. doi:10.3109/10253890.2013.876404
6. Andersson NW, Hansen MV, Larsen AD, Hougaard KS, Kolstad HA, Schlüßlen V. Prenatal maternal stress and atopic diseases in the child: a systematic review of observational human studies. Allergy. 2016;71(1):15-26. doi:10.1111/all.12762. http://www.ncbi.nlm.nih.gov/pubmed/26395995
7. Guxens M, van der Sonnenschein Voort AMM, Tiemeier H, et al. Parental psychological distress during pregnancy and wheezing in preschool children: the Generation R Study. J Allergy Clin Immunol. 2014;133(1):59-67.e12. 10.1016/j.jaci.2013.04.044. http://www.ncbi.nlm.nih.gov/pubmed/23777854
8. Wang Jj, Wen Hj, Chiang Tl, Lin Sj, Chen PC, Guo YL. Maternal employment and atopic dermatitis in children: a prospective cohort study. Br J Dermatol. 2013;168:794-801. doi:10.1111/bjd.12195
9. Cheng TS, Chen H, Lee T, et al. An independent association of prenatal depression with wheezing and anxiety with rhinitis in infancy. Pediatr Allergy Immunol. 2015;26(8):765-771. doi:10.1111/pai.12453. http://www.ncbi.nlm.nih.gov/pubmed/26235785
10. Chiu CY, Huang YL, Tsai MH, et al. Sensitization to food and inhalant allergens in relation to atopic diseases in early childhood: a birth cohort study. PLoS One. 2014;9(7):e102809. doi:10.1371/journal.pone.0102809
11. Chang HY, Suh DI, Yang SI, et al. Prenatal maternal distress affects atopic dermatitis in offspring mediated by oxidative stress. J Allergy Clin Immunol. 2016;138:468-475.e5. doi:10.1016/j.jaci.2016.01.020
12. Wen Hj, Wang Yj, Lin Yc, et al. Prediction of atopic dermatitis in 2-year-old children by cord blood IgE, genetic polymorphisms in cytokine genes, and maternal mentality during pregnancy. Pediatr Allergy Immunol. 2011;22:695-703. doi:10.1111/j.1399-3038.2011.01177.x
13. Rosa MJ, Lee AG, Wright RJ. Evidence establishing a link between prenatal and early-life stress and asthma development. Curr Opin Allergy Clin Immunol. 2018;18(2):148-158. doi:10.1097/ACI.0000000000000421. https://pubmed.ncbi.nlm.nih.gov/29369067/
14. Lukkarinen M, Puosi E, Kataja E, et al. Maternal psychological distress during gestation is associated with infant food allergy. Pediatr Allergy Immunol. 2021;32(4):787-792. doi:10.1111/pai.13449
15. de Marco R, Pesce G, Girardi P, et al. Foetal exposure to maternal stressful events increases the risk of having asthma and atopic diseases in childhood. Pediatr Allergy Immunol. 2012;23(8):724-729. doi:10.1111/j.1399-3038.2012.01346.x. http://www.ncbi.nlm.nih.gov/pubmed/22957808
16. Reyes M, Perzanowski MS, Whyatt RM, et al. Relationship between maternal demoralization, wheeze, and immunoglobulin E among inner-city children. Ann Allergy Asthma Immunol. 2011;107(1):42-49. e1. doi:10.1016/j.anai.2011.03.004. http://www.ncbi.nlm.nih.gov/pubmed/21704884
17. Pacheco-Gonzalez RM, Mallol J, Solé D, et al. Factors associated with the time to the first wheezing episode in infants: a cross-sectional study from the International Study of Wheezing in Infants (EISL). NPJ Prim Care Respir Med. 2016;26(1):15077. doi:10.1038/npjpcm.2015.77. http://www.nature.com/articles/npjpcm201577
18. Chiu Y-HM, Coull BA, Cohen S, Wooley A, Wright RJ. Prenatal and postnatal maternal stress and wheeze in urban children: effect of maternal sensitization. Am J Respir Crit Care Med. 2012;186(2):147-154. doi:10.1164/rccm.201201-0162OC
19. Rosa MJ, Just AC, Ortiz TY, et al. Prenatal and postnatal stress and wheeze in Mexican children: sex-specific differences. Ann Allergy Asthma Immunol. 2016;116:306-312.e1. doi:10.1016/j.anai.2015.12.025
20. Karlsson L, Tolvanen M, Scheinin NM, et al. Cohort profile: the FinnBrain Birth Cohort Study (FinnBrain). Int J Epidemiol. 2018;47(1):15-16. doi:10.1093/ije/dyx173. http://www.ncbi.nlm.nih.gov/pubmed/29025073
21. Jaakkola JJK, Ahmed P, Ieromnimon A, et al. Preterm delivery and asthma: a systematic review and meta-analysis. *J Allergy Clin Immunol*. 2006;118:823-830. doi:10.1016/j.jaci.2006.06.043

22. Bergink V, Kooistra L, van den Lambregtse Berg MP, et al. Validation of the Edinburgh Depression Scale during pregnancy. *J Psychosom Res*. 2011;70(4):385-389. doi:10.1016/j.jpsychores.2010.07.008. https://pubmed.ncbi.nlm.nih.gov/21414460/

23. Korja R, Nolvi S, Kataja EL, et al. The courses of maternal and paternal depressive and anxiety symptoms during the prenatal period in the Finnbrain birth cohort study. *PLoS One*. 2018;13(12):e0207856. doi:10.1371/journal.pone.0207856

24. Muthén L, Muthén B. *Mplus User’s Guide*. 6th ed. Muthén & Muthén; 2012. doi:10.1111/j.1600-0447.2011.01711.x

25. Asher MI, Keil U, Anderson HR, et al. International study of asthma and allergies in childhood (ISAAC): rationale and methods. *Eur Respir J*. 1995;8(3):483-491. doi:10.1183/09031936.95.08030483. http://erj.ersjournals.com/content/8/3/483

26. Abuabara K, Yu AM, Okhovat J-P, Allen IE, Langan SM. The prevalence of atopic dermatitis beyond childhood: a systematic review and meta-analysis of longitudinal studies. *Allergy*. 2018;73(3):696-704. doi:10.1111/all.13320. http://www.ncbi.nlm.nih.gov/pubmed/28960336

27. Korhonen LS, Karlsson L, Scheinin NM, et al. Prenatal maternal psychological distress and offspring risk for recurrent respiratory infections. *J Pediatr*. 2019;208:229-235.e1. doi:10.1016/j.jpeds.2018.12.050. https://pubmed.ncbi.nlm.nih.gov/30723014/

28. Lukkarinen M, Koistinen A, Turunen R, Lehtinen P, Vuorinen T, Jartti T. Rhinovirus-induced first wheezing episode predicts atopic but not nonatopic asthma at school age. *J Allergy Clin Immunol*. 2017;140(4):988-995. doi:10.1016/j.jaci.2016.12.991. http://www.ncbi.nlm.nih.gov/pubmed/28347734

29. Goksör E, Alm B, Pettersson R, et al. Early fish introduction and neonatal antibiotics affect the risk of asthma into school age. *Pediatr Allergy Immunol*. 2013;24(4):339-344. doi:10.1111/pai.12078

30. Nissen SP, Kjaer HF, Hæst A, Nielsen J, Halken S. The natural course of sensitization and allergic diseases from childhood to adulthood. *Pediatr Allergy Immunol*. 2013;24:549-555. doi:10.1111/pai.12108

31. Uphoff EP, Bird PK, Antó JM, et al. Variations in the prevalence of childhood asthma and wheeze in MeDALL cohorts in Europe. *ERJ Open Res*. 2017;3(3):e00150-2016. doi:10.1183/23120541.00150-2016. https://pubmed.ncbi.nlm.nih.gov.ezproxy.utu.fi/28845428/

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

---

**How to cite this article:** Puosi E, Korhonen LS, Karlsson L, et al. Maternal prenatal psychological distress associates with offspring early-life wheezing – FinnBrain Birth Cohort. *Pediatr Allergy Immunol*. 2022;33:e13706. doi:10.1111/pai.13706